Research programme: genetic disorder therapeutics - BioBlast Pharma

Drug Profile

Research programme: genetic disorder therapeutics - BioBlast Pharma

Alternative Names: BB-FA; BB-OTC; BBrm 01; BBrm02; BBrm1; Intrathecal azithromycin - BioBlast

Latest Information Update: 14 Jul 2015

Price : $50

At a glance

  • Originator Bioblast Pharma
  • Class Macrolides; Proteins; Small molecules
  • Mechanism of Action Frataxin protein replacements; Gene expression modulators; Ornithine carbamoyltransferase replacements; Survival of motor neuron 2 protein expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Friedreich's ataxia; Inborn urea cycle disorders; Spinal muscular atrophy

Most Recent Events

  • 22 Jun 2015 Pharmacodynamics data from a preclinical trial in spinal muscular atrophy released by BioBlast Pharma
  • 22 Jun 2015 BioBlast plans a phase IIa trial for Spinal muscular atrophy in USA
  • 26 Mar 2015 Pharmacodynamics data from preclinical trial in Friedreich's ataxia released by BioBlast
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top